LV10051A - How to get lyophilisate ifosfamida - Google Patents

How to get lyophilisate ifosfamida

Info

Publication number
LV10051A
LV10051A LV920174A LV920174A LV10051A LV 10051 A LV10051 A LV 10051A LV 920174 A LV920174 A LV 920174A LV 920174 A LV920174 A LV 920174A LV 10051 A LV10051 A LV 10051A
Authority
LV
Latvia
Prior art keywords
ifosfamida
lyophilisate
ifosfamide
weight
hexitol
Prior art date
Application number
LV920174A
Other languages
Latvian (lv)
Other versions
LV10051B (en
Inventor
Uwe-Peter Damann
Otto Isaac
Dieter Sauerbier
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of LV10051A publication Critical patent/LV10051A/en
Publication of LV10051B publication Critical patent/LV10051B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Abstract

1. A lyophilized preparation consisting of ifosfamide and 0.1 to 17 parts by weight hexitol per part by weight ifosfamide and, optionally, other standard pharmaceutical auxiliaries.
LVP-92-174A 1986-10-31 1992-10-27 Method for producing of lyophilized yphosphamide LV10051B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3637089 1986-10-31

Publications (2)

Publication Number Publication Date
LV10051A true LV10051A (en) 1994-05-10
LV10051B LV10051B (en) 1995-06-20

Family

ID=6312873

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-174A LV10051B (en) 1986-10-31 1992-10-27 Method for producing of lyophilized yphosphamide

Country Status (25)

Country Link
EP (1) EP0265812B1 (en)
JP (1) JPS63159319A (en)
KR (1) KR900003491B1 (en)
AT (1) ATE55250T1 (en)
AU (1) AU598602B2 (en)
CA (1) CA1314231C (en)
DD (1) DD262582A5 (en)
DE (1) DE3764235D1 (en)
DK (1) DK169308B1 (en)
EG (1) EG18333A (en)
ES (1) ES2017982B3 (en)
FI (1) FI87140C (en)
GE (1) GEP19971025B (en)
GR (1) GR3000708T3 (en)
HU (1) HU197987B (en)
IL (1) IL84312A (en)
IN (1) IN168119B (en)
LV (1) LV10051B (en)
MX (1) MX8958A (en)
NO (1) NO873860L (en)
PT (1) PT86032B (en)
RU (1) RU1836079C (en)
UA (1) UA11075A (en)
YU (1) YU197387A (en)
ZA (1) ZA878183B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE65402T1 (en) * 1988-03-19 1991-08-15 Asta Pharma Ag IFOSFAMIDE MESNA LYOPHILISATE AND PROCESS FOR PRODUCTION THEREOF.
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
DE19529057B4 (en) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamide lyophilizate preparations
WO1999044604A1 (en) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
AU2003276689B2 (en) * 2002-09-05 2009-04-09 Bharat Serums And Vaccines Ltd. Liquid stable composition of oxazaphosphorine with mesna
ES2342380T3 (en) * 2002-12-02 2010-07-06 BHARAT SERUMS & VACCINES LTD. IFOSFAMIDE COMPOSITIONS FOR PARENTERAL ADMINISTRATION AND A PROCEDURE FOR PREPARATION.
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
DK2071917T3 (en) * 2006-09-29 2013-03-04 Infa Sa Packaging system for pharmaceutical compositions and kits for intravenous administration
WO2016087001A1 (en) * 2014-12-04 2016-06-09 Huawei Technologies Co., Ltd. Load allocation in a data communication network

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
DE2750207A1 (en) * 1977-05-09 1978-11-16 Walton J Smith Anhydrous compsn. prodn. by freeze drying hydrated, hydrolysable prod. - esp. aspirin or aspirin salt solns.
DE3279834D1 (en) * 1981-12-31 1989-08-31 Asta Pharma Ag 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide

Also Published As

Publication number Publication date
FI87140C (en) 1992-12-10
HU197987B (en) 1989-07-28
PT86032A (en) 1987-11-01
JPH0543684B2 (en) 1993-07-02
IL84312A (en) 1991-11-21
YU197387A (en) 1988-12-31
IN168119B (en) 1991-02-09
AU598602B2 (en) 1990-06-28
ATE55250T1 (en) 1990-08-15
EG18333A (en) 1993-12-30
AU8052987A (en) 1988-05-05
CA1314231C (en) 1993-03-09
GR3000708T3 (en) 1991-10-10
MX8958A (en) 1993-12-01
GEP19971025B (en) 1997-04-06
IL84312A0 (en) 1988-03-31
DK169308B1 (en) 1994-10-10
HUT44932A (en) 1988-05-30
DK569687A (en) 1988-05-01
RU1836079C (en) 1993-08-23
FI874727A (en) 1988-05-01
FI87140B (en) 1992-08-31
ES2017982B3 (en) 1991-03-16
EP0265812B1 (en) 1990-08-08
NO873860D0 (en) 1987-09-15
ZA878183B (en) 1988-05-02
KR900003491B1 (en) 1990-05-21
DK569687D0 (en) 1987-10-30
UA11075A (en) 1996-12-25
DE3764235D1 (en) 1990-09-13
LV10051B (en) 1995-06-20
PT86032B (en) 1990-08-31
JPS63159319A (en) 1988-07-02
FI874727A0 (en) 1987-10-27
KR880004814A (en) 1988-06-27
EP0265812A1 (en) 1988-05-04
DD262582A5 (en) 1988-12-07
NO873860L (en) 1988-05-02

Similar Documents

Publication Publication Date Title
FI891283A0 (en) IFOSFAMID-MESNA-LYOFILISAT AND FOERFARANDE FOER DESS FRAMSTAELLNING.
DE3855451D1 (en) Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DK275488D0 (en) indolone derivatives
ATE66143T1 (en) SLOW RELEASE SOLID PREPARATION.
GR890100838A (en) A novel therapeutic active compound and preparation method therefore.
DE3766200D1 (en) L-DOPA CONTAINING MEDICINAL PRODUCT.
PH23565A (en) Novel pyrimidinylpyrimidine derivatives and a plant disease protectant containing them as the active ingredient
LV10051A (en) How to get lyophilisate ifosfamida
IT1212143B (en) COMPOSITION WITH TRICHOGENIC ACTIVITY.
DK23490A (en) IMPLANTED ANTIBIOTIC PREPARATION WITH REGULATED RELEASE
FR2603284B1 (en) 7-OXABICYCLO ACID DERIVATIVES (2.2.1.) HYDROXAMIC HEPTANE WITH THERAPEUTIC ACTION
KR900700484A (en) Aminopropanol derivative of 1,4: 3,6-dianhydro hexitol salate, its preparation and use as a medicament
DE3773322D1 (en) PHARMACEUTICAL PREPARATIONS WITH HEALING ACTIVITY.
IT213056Z2 (en) TIPS TO ASSEMBLE THE OPENERS ON AGRICULTURAL TRACTORS WITHOUT AFFECTING THE NECESSARY MECHANICAL STRENGTH OF THE SET